유세포 분석 시장 : 시장 인사이트, 경쟁 환경 및 시장 예측(-2030년)

Flow Cytometry Market By Product And Services Type (Instruments, Kits & Reagents, And Others), By Technology Type (Cell-Based Flow Cytometry And Bead-Based Flow Cytometry), By Application (Oncology, Drug Discovery, Stem Cell Therapy, , Hematology, Immunology, And Other Applications), By End User (Academic & Research Institutes, Hospitals, Clinical Testing Laboratories, And Others), by geography is expected to grow at a healthy CAGR forecast till 2030 owing to the increasing research and development activities and rising prevalence of cancer and immunodeficiency disorders such as human immunodeficiency virus infection (hiv) & acquired immune deficiency syndrome (aids) and cancer

Global flow cytometry market was valued at USD 4,942.02 million in 2023, growing at a CAGR of 7.52% during the forecast period from 2024 to 2030 to reach USD 7,587.63 million by 2030. The increase in demand for flow cytometry is primarily attributed to the rising research and development activities in healthcare industry. Further, rising prevalence of chronic and immunological ailments like HIV & AIDS and cancer due to gene mutations, such as smoking, radiation, viruses, cancer-causing chemicals (carcinogens), obesity, hormones, chronic inflammation, and a lack of exercise. The diagnosis of HIV & AIDS and cancer is done by flow cytometry thereby increasing the the demand of the device in the market. Additionally, rising advancements in stem cell research and recombinant DNA technology in the development of cancerous and immunology drugs and increasing advancements in flow cytometry softwares such as, providing high-resolution imaging, fluorescence and laser technology, and others across the world are anticipated to bolster the market, thereby contributing to the growth of the flow cytometry market during the forecast period from 2024-2030.

Flow Cytometry Market Dynamics:

The flow cytometry market is witnessing a growth in product demand owing to various reasons. The rising prevalence of chronic disorders such as HIV & AIDS and cancer across the world are anticipated to bolster the market. The flow cytometry is used to diagnose the disorder in a patient. Moreover, rising advancements in stem cell research and recombinant DNA technology in the development of cancerous and immunology drugs will propel the demand of flow cytometers in the market, thereby increasing the overall market growth of the flow cytometry.

For instance, according to the study done by World Health Organization (WHO) in the year 2020, it was estimated that globally 79.3 million people were infected with the HIV virus and about 36.3 million people died due to HIV. Flow cytometry technique is used to diagnose the presence of HIV virus in a patient. It determines the antigen status of HIV-seropositive patient. The incidence and the mortality rate can be controlled by providing early diagnosis and treatment to the patient. Thus, as the prevalence of HIV is increasing globally which in turn is surging the number of diagnostic test performed for the disease, ultimately increasing the demand of flow cytometry. Therefore, increasing the overall market of flow cytometry.

Moreover, technological advancements in flow cytometry will act as a driving factor for the market. Advancements like live-cell imaging, super-resolution, fluorescence and laser technology, high-resolution imaging, examination of intracellular compartments of the cells, and digitalization will drive the market of flow cytometry during the forecast period.

For instance, in April 2022, Sysmex Europe, a trusted provider of automated workflow solutions in the disciplines of hematology, urinalysis and hemostasis, announced the launch of its Flow Cytometer XF-1600, which has received CE marking. XF-1600 offers clinical flow cytometry laboratories a robust, high-performance 10-colour analyzer for highly efficient and reliable data collection for immunophenotyping.

Hence, various applications and technological advancements in the area of flow cytometry will increase the market demand of the instrument leading to an overall rise in the flow cytometry market growth during the forecast period of 2024-2030.

However, high cost of flow cytometers and dearth of skilled professionals in remote regions may hamper the flow cytometry market growth.

The ongoing COVID-19 pandemic has significantly impacted the market for flow cytometry as the research & developmental activities were halted for some time. During the initial phase of pandemic, the market had witnessed little downfall due to stringent lockdown guidelines and social distancing norms. The supply of raw materials and other resources were also not available due to which the key players in the market stopped their manufacturing units, ultimately leading to the decline in the stock of the device in the market. But, with the normalcy and with the return of resources, the market picked up the momentum again. The research & developmental industry demanded the device for the analysis of viral and chronic diseases. Owing to this fact, the leading market players accelerated their production of flow cytometers thereby increasing the market demand of the flow cytometry, in turn, propelling the market growth of flow cytometry during the forecast period of 2024-2030.

Flow Cytometry Market Segment Analysis:

Flow Cytometry Market by Product and Services Type (Instruments, Kits & Reagents, and Others), by Technology Type (Cell-Based Flow Cytometry and Bead-Based Flow Cytometry), by Application (Oncology, Drug Discovery, Stem Cell Therapy, , Hematology, Immunology, and Other Applications), by End User (Academic & Research Institutes, Hospitals, Clinical Testing Laboratories, andOthers), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the technology type segment of the flow cytometry market, the cell-based flow cytometry is estimated to hold a significant share in the flow cytometry market in the year 2023. This can be ascribed to the various advantages that are associated with the technology.

The cell-based flow cytometry technology offers screening of cell using cell-based assays. It has the advantage of testing the effects of compounds against molecular targets within the context of living cells. The technology also comprise of broad, systematic biology approaches for understanding cellular mechanisms involved in disease processes.

Additionally, the technology enables the drug discovery scientists to develop models of interconnected cellular pathways, extract important information for specific disease models, and build companion diagnostic programs around relevant cellular biomarkers for therapeutics.

Moreover, automated technologies are also evolving for cell-based technology. Real-time intracellular calcium response measurements, high-content fluorescent imaging systems, the ability to screen compounds against required targets in the context of living cells, and other advancements are being incorporated in the cell-based flow cytometry. Moreover, the product launches pertaining to the flow cytometry devices, in turn, drive the product demand in the market. For instance, in June 2022, Thermo Fisher Scientific, is one of the world leader in serving science in scientific instrumentation, reagents and consumables, and software, announced that they have launched Invitrogen Attune CytPix Flow Cytometer, an imaging-enhanced flow cytometer that combines acoustic focusing flow cytometry technology with a high-speed camera.

Thus, owing to the various advantages and applications offered by the cell-based flow cytometry technology and an increase in the launch and approvals of the cell-based flow cytometer, there will be an increase in the demand for cell-based flow cytometry, which in turn will drive the flow cytometry market growth.

North America is expected to dominate the overall Flow Cytometry Market:

Among all the regions, North America is estimated to achieve a significant share in the global flow cytometry market. Increasing research & developmental activities such as, drug development for various chronic disorders and diagnosis of different bacteria & viral structures present in a patient's blood and the rising prevalence of cancer due to gene mutations, such as smoking, radiation, viruses, cancer-causing chemicals (carcinogens), obesity, hormones, chronic inflammation, and a lack of exercise will increase the demand for flow cytometry in North America, leading to a rise in the overall flow cytometry market growth.

For instance, according to Cancer Facts & Figures 2022, as per a scientific paper published in the American Cancer Society journal, it was estimated that in 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. The paper also concluded that cancer is the second most common cause of death in the US, after the heart diseases. Additionally, flow cytometry technique is used for the detection of tumor cell DNA aneuploidy, for the analysis of tumor cell proliferation and for the immunophenotyping of leukemia. The increasing prevalence of cancer across the United States will increase the demand of flow cytometry technique for the diagnostic purpose. Thus, the increasing demand of flow cytometry will propel the overall market growth of the device in the North America during the forecast period.

Moreover, flow cytometry analyzes a large number of particles in a short period and provide statistically robust information about cell populations. These abilities, coupled with multi-parametric approach of the device will facilitate the adoption of flow cytometry in drug discovery and development processes in the healthcare industry. Furthermore, flow cytometry is also widely used in biomarker research to monitor the development and differentiation of cell populations, evaluating the target engagement and biomarker expression in cells, and assessing the cell functions and signaling events. The increasing demand of flow cytometry in the research & developmental industries will bolster the market of the device in the forecast period of 2022 - 2028. Thus, increasing the overall market growth of the device in the North America.

Additionally, the increasing presence of highly developed research institutes and laboratories in North America is one of the major factor driving the flow cytometry market in the region. The rise in demand and application of cellular biology for stem cells and cancer cells research, and the growth and advancement in the field of biomedical engineering, expansion of contact research organizations in North America will also boost the demand for flow cytometry. Moreover, the growing adoption of technologically advanced flow cytometry such as fluorescence and laser technology, high-resolution imaging, examination of intracellular compartments of the cells, and digitalization will further boost the demand of the device in the North America, leading to a rise in the overall flow cytometry market growth.

Thus, all the above-mentioned factors are anticipated to propel the market for flow cytometry in the North America.

Flow Cytometry Market Key Players:

Some of the key market players operating in the flow cytometry market include Thermo Fisher Scientific Inc., BD, Stratedigm, Inc, Bio-Rad Laboratories, Inc., Luminex Corporation., Miltenyi Biotec, Sysmex Corporation, Agilent Technologies, Inc., Sony Biotechnology Inc., bioMerieux SA, Enzo Life Sciences, Inc., Union Biometrica, Inc., Cytek Biosciences, Sartorius AG, Beckman Coulter, Inc., Apogee Flow Systems Ltd., Molecular Instruments, Inc., Integrated DNA Technologies, Inc., New England Biolabs (NEB), ACROBiosystems, among others.

Recent Developmental Activities in the Flow Cytometry Market:

In April 2022, BD, a leading global medical technology company, announced the launch of a new family of reagents, Horizon RealYellow 586 Reagents that enables researchers to gain improved data resolution and greater insights from samples as compared to traditional fluorochromes. The launch of BD Horizon RealYellow 586 Reagents marks the first fluorochrome in a series from the new BD Horizon RealYellow and RealBlue Reagents product family. These reagents are a significant breakthrough in flow cytometry and have the potential to accelerate discovery and drug development in many diseases.

In February 2022, KCAS, a U.S.-based contract research organization (CRO) providing GLP-compliant bioanalytical and biomarker development testing services for the biotech, pharmaceutical, and cell/gene therapy industries, has acquired FlowMetric, LLC, a provider of flow cytometry and cellular assay R&D services to biotech, pharmaceutical and cell/gene therapy industries.

In August 2022, BD, a global medical technology company, announced the launch of a new benchtop cell analyzer- FACSymphony A1 Cell Analyzer that brings sophisticated flow cytometry capabilities to laboratories of all sizes. The analyzer is a fluorescence-activated cell analyzer that offers advanced research capabilities in a compact design, which helps improve access to instrumentation for complex scientific research to more labs.

Key Takeaways from the Flow Cytometry Market Report Study

• Market size analysis for current flow cytometry market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the flow cytometry market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global flow cytometry market.
• Various opportunities available for the other competitor in the flow cytometry market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current flow cytometry market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for flow cytometry market growth in the coming future?

Target Audience who can be benefited from this Flow Cytometry Market Report Study

• Flow cytometry products providers
• Research organizations and consulting companies
• Flow cytometry-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in flow cytometry
• Various End-users who want to know more about the flow cytometry market and latest technological developments in the flow cytometry market.

Frequently Asked Questions for Flow Cytometry Market:

1. What are Flow cytometry?

Flow cytometry, is a technology that provides rapid multi-parametric analysis of single cells in solution. Flow cytometers utilize lasers as light sources to produce both scattered and fluorescent light signals that are read by detectors such as photodiodes or photomultiplier tubes. The instrument used in the analysis is known as flow cytometer. The technology has applications in immunology, molecular biology, bacteriology, virology, cancer biology, and infectious disease monitoring

2. What is the market for Global Flow cytometry?

Global flow cytometry market was valued at USD 4,942.02 million in 2023, growing at a CAGR of 7.52% during the forecast period from 2024 to 2030 to reach USD 7,587.63 million by 2030.

3. What are the drivers for the Global Flow cytometry Market?

The flow cytometry market is witnessing a positive market growth owing to increasing research and development activities, rising prevalence of cancer and immunodeficiency disorders, rising advancements in stem cell research and recombinant DNA technology, increasing advancements in flow cytometry software across the world are anticipated to bolster the market.

4. Who are the key players operating in the Global Flow cytometry Market?

Some of the key market players operating in the flow cytometry market include Thermo Fisher Scientific Inc., BD, Stratedigm, Inc, Bio-Rad Laboratories, Inc., Luminex Corporation., Miltenyi Biotec, Sysmex Corporation, Agilent Technologies, Inc., Sony Biotechnology Inc., bioMerieux SA, Enzo Life Sciences, Inc., Union Biometrica, Inc., Cytek Biosciences, Sartorius AG, Beckman Coulter, Inc., Apogee Flow Systems Ltd., Molecular Instruments, Inc., Integrated DNA Technologies, Inc., New England Biolabs (NEB), ACROBiosystems, and others.

5. Which region has the highest share in Flow cytometry Market?

North America is expected to hold the highest share in the revenue in the flow cytometry market during the forecast period. Increasing research and development activities and rising prevalence of chronic and infectious disease like cancer and AIDS will increase the demand for flow cytometry in North America, leading to a rise in the overall flow cytometry market growth in this region.

Table of Contents

1.Flow cytometry Market Report Introduction

2.Flow cytometry Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Flow cytometry Market Key Factors Analysis

• 4.1. Flow cytometry Market Drivers
  • 4.1.1. Increasing research and development activities
  • 4.1.2. Rising prevalence of cancer and immunodeficiency disorders
  • 4.1.3. Rising advancements in stem cell research and recombinant DNA technology
  • 4.1.4. Increasing advancements in flow cytometry software
• 4.2. Flow cytometry Market Restraints and Challenges
  • 4.2.1. High cost of flow cytometers
  • 4.2.2. Dearth of skilled professionals in remote regions
• 4.3. Flow cytometry Market Opportunities
  • 4.3.1. Increasing incorporation of Artificial Intelligence platforms in flow cytometry workflows

5. Flow cytometry Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Flow cytometry Market

7. Flow cytometry Market Layout

• 7.1. By Product and Services Type
  • 7.1.1. Instruments
  • 7.1.2. Kits and Reagents
  • 7.1.3. Others
• 7.2. By Technology Type
  • 7.2.1. Cell-based Flow Cytometry
  • 7.2.2. Bead-based Flow Cytometry
• 7.3. By Application
  • 7.3.1. Oncology
  • 7.3.2. Drug Discovery
  • 7.3.3. Stem Cell Therapy
  • 7.3.4. Hematology
  • 7.3.5. Immunology
  • 7.3.6. Other applications
• 7.4. By End User
  • 7.4.1. Academic & Research Institutes
  • 7.4.2. Hospitals
  • 7.4.3. Clinical Testing Laboratories
  • 7.4.4. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States
    • 7.5.1.2. Canada
    • 7.5.1.3. Mexico
  • 7.5.2. Europe
    • 7.5.2.1. France
    • 7.5.2.2. Germany
    • 7.5.2.3. United Kingdom
    • 7.5.2.4. Italy
    • 7.5.2.5. Spain
    • 7.5.2.6. Russia
    • 7.5.2.7. Rest of Europe
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China
    • 7.5.3.2. Japan
    • 7.5.3.3. India
    • 7.5.3.4. Australia
    • 7.5.3.5. South Korea
    • 7.5.3.6. Rest of Asia Pacific
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. Middle East
    • 7.5.4.2. Africa
    • 7.5.4.3. South America

8. Flow cytometry Market Global Company Share Analysis - Key 3-5 Companies

9. Flow cytometry Market Company and Product Profiles

• 9.1. Thermo Fisher Scientific Inc.
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. BD
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Stratedigm, Inc
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Bio-Rad Laboratories, Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Luminex Corporation.
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. Miltenyi Biotec
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Sysmex Corporation
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Agilent Technologies, Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Sony Biotechnology Inc.
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. bioMerieux SA
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Enzo Life Sciences, Inc.,
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. Union Biometrica, Inc.
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Cytek Biosciences
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Sartorius AG
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Beckman Coulter, Inc.
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. Apogee Flow Systems Ltd.
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Molecular Instruments, Inc.
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Integrated DNA Technologies, Inc.
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. New England Biolabs (NEB)
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. ACROBiosystems
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us